Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2609 in Early Alzheimer's Disease
CTR20180251Phase 3Suspended
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elenbecestat in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd.. Started Mar 2018; status: suspended.
02
Drugs
elenbecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20180251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180251.